HAPHARM GROUP:R&D will focus on five major areas and three directions, including cardiovascular and cerebrovascular

July 19, 2024

On July 18, HAPHARM GROUP disclosed an investor activity record sheet showing that in terms of research and development, the company focuses on five major areas, namely cardiovascular and cerebrovascular, digestive metabolism, respiratory, anti-infection and anti-tumor; and focuses on three directions: medicines for the elderly, medicines for children, and general health products.

HAPHARM GROUP is a large enterprise group integrating pharmaceutical manufacturing, trade and scientific research. The company covers two core business sectors: pharmaceutical industry and pharmaceutical commerce. It has 1,802 drug approvals and 122 health food approvals. Products with sales of over 100 million yuan include zinc gluconate oral solution, compound calcium gluconate oral solution, calcium iron zinc oral solution, Shuanghuanglian oral solution, amoxicillin capsules, lacidipine tablets, roxatidine acetate hydrochloride for injection, recombinant human erythropoietin injection (CHO cells), pediatric acetaminophen granules, ibuprofen granules, etc.

HAPHARM GROUP has a comprehensive and systematic R&D system including Harbin Pharmaceutical Group Technology Center, Harbin Pharmaceutical (Beijing) Biotechnology Co., Ltd., and special research centers (biological drug research center; pharmaceutical preparation engineering center; OTC drug and health food research center; animal vaccine and veterinary drug research center). It is committed to the research and development of high-tech products such as innovative drugs and generic drugs with technical barriers, taking into account consistency evaluation, health foods, etc., while improving the level of industrial technology. We are building a number of specialized technology platforms, including children's drug delivery technology platform, sustained-release preparation technology platform, transdermal drug delivery technology platform, chemical raw material continuous flow R&D technology platform, and new drug R&D technology platform, to enhance the company's core competitiveness and provide more conscientious medicines for human health.